Adults with blood cancers respond to booster, not initial dose of COVID-19 vaccine
New coronavirus mutant raises concerns in India and beyond
11 July 2022Heart-healthy, lower sodium version of traditional Chinese cuisine lowered blood pressure
11 July 2022Adults with blood cancers respond to booster, not initial dose of COVID-19 vaccine
People with hematologic malignancies—or blood cancers including leukemia, lymphoma, and multiple myeloma—have an impaired immune system due to their disease and its treatment, putting them at risk of severe COVID-19 infection and experiencing a reduced response to COVID-19 vaccination. In a recent study published by Wiley online in Cancer, a peer-reviewed journal of the American Cancer Society, less than half of patients with hematologic malignancies mounted detectable antibodies after initial COVID-19 vaccination, but 56% of “nonresponders” produced antibodies after receiving a booster dose.
